Over 2 billion yuan raised in two months, Xingdong Jiyuan continues to replenish its ammunition.
```
Author | Huang Yu
As the commercialization of humanoid robots accelerates, capital continues to pour into this popular track.
According to Wall Street News, after completing a strategic round of financing of 1 billion RMB in March this year, Xingdong Era has recently completed a new round of financing of over $200 million.
This means that within just two months, Xingdong Era has raised nearly 2.5 billion RMB in total. Including last November’s Series A+ financing, Xingdong Era has raised nearly 3.5 billion RMB in total over the past six months.
When Xingdong Era completed its 1 billion RMB financing in March, market sources said that its valuation had surpassed 10 billion RMB.
The latest round of financing for Xingdong Era featured a large group of investors, including both investment institutions and multiple industrial partners.
Specifically, the round was led by SF Group, with joint funding from well-known institutions such as Sequoia China, IDG Capital, CICC Capital, Jingming Capital, Chaoxi Capital, Luxin Venture Capital, Juhe Capital, Longqi Investment, etc.; multiple leading industrial partners such as Cogent Intelligent, Dongfeng Industrial Investment, ICBC Capital, and a fund under Unicom also participated; existing shareholders Qingkong Tiancheng and Hongruida continued to increase their holdings.
Xingdong Era was established in August 2023, focusing on the humanoid robot field. Based on full-stack self-research (brain - control - data - dexterous hand - humanoid body), it is building a complete “real working” robot AI Native system-level capability.
After multiple rounds of financing, Xingdong Era’s shareholders include top investment institutions such as CDH VGC, Sequoia China, IDG Capital, and CICC Capital, as well as industry giants including SF Group, Alibaba, Geely Capital, BAIC, Dongfeng, Samsung Group, Lenovo, Haier, etc.
As is well known, for embodied intelligence enterprises still at the stage of exploring scaled commercial deployment, support from both capital and industry partners is required to enable exploration of embodied intelligence in real scenarios.
In 2025, the global humanoid robot market will reach a point of scale.
IDC data shows that global humanoid robot shipments for the year will approach 18,000 units, a year-on-year increase of about 508%, with sales totaling about $440 million; Meanwhile, the cumulative sales order volume is expected to exceed 35,000 units, laying the foundation for subsequent delivery and continued market release.
Although growth is impressive, it must be admitted that the scale of mass production of humanoid robots is still very small. According to Omdia data, last year only three companies shipped more than 1,000 units, all from China: Zhiyuan Robotics, Unitree Technology, and UBTECH, with respective shipments of 5,168 units, 4,200 units, and 1,000 units.
2025 is also a very important year for Xingdong Era. CEO Chen Jianyu defines this year as the “dual-track year of technical breakthroughs and commercialization verification.”
It is reported that Xingdong Era’s first truly commercialized order will appear in 2025, from an overseas scientific research client who values the Xingdong XHAND1 five-finger dexterous hand.
However, in terms of whole machine shipments, Xingdong Era still lags behind the leading players in the industry.
Chen Jianyu believes 2026 will be the key year for embodied intelligence to move from technical validation to commercial landing.
“My prediction is: as long as there is no external ‘black swan’ event, embodied intelligence will remain hot throughout 2026. On one hand, it is driven by expectations in the external economy and investment markets; on the other, technical iteration is accelerating, and many tasks previously believed impossible are being gradually overcome.”
Based on this, Chen Jianyu proposes that in 2026, Xingdong Era aims to achieve shipments at a thousand-unit scale, and the longer-term target is ten thousand units. The current greatest constraint in the industry is not supply chain or delivery capability, but demand validation and product refinement.
In his view, there are many ways to reduce robot costs. Thanks to China's manufacturing capabilities, lowering hardware cost is not a problem—but the primary goal is to get the product running smoothly, because product validation is harder and more crucial than cost optimization.
It is reported that Xingdong Era has now completed the first Product-Market Fit (PMF) in the embodied intelligence industry, with deployments in the logistics sector and cooperation with China Post, SF Express, and others in over ten logistics centers.
In addition, Xingdong Era revealed that in the second quarter of 2026, it began batch delivery at a thousand-unit scale, with a growth rate as high as 300%.
IDC predicts several leading Chinese manufacturers are expected to achieve ten-thousand-unit capacity in 2026, further strengthening their scaled supply capabilities and likely continuing to consolidate their first-mover advantages.
By 2030, global shipments of humanoid robots will exceed 510,000 units, with an annual compound growth rate of nearly 95%. With upgrades to the main body technology, deeper exploration of application value, co-building of industry ecosystems, and continuous improvement of business models, future industry competition will focus on application capabilities and delivery of business value.
Undoubtedly, the mass production of humanoid robots will enter an accelerated phase next.
To avoid being squeezed out in fierce market competition, in addition to improving technical capabilities, continuously strengthening abilities to achieve commercial landing is also a challenge all major humanoid robot manufacturers must overcome.
Risk Disclosure and DisclaimerThe market has risks, investment requires caution. This article does not constitute personal investment advice, nor does it take into account individual users’ special investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article suit their specific circumstances. Investing based on this article is at your own risk. ```